• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术前评分鉴别乳腺纤维上皮性病变:叶状肿瘤还是纤维腺瘤?

A Pre-operative Score to Discriminate Fibroepithelial Lesions of the Breast: Phyllode Tumor or Fibroadenoma?

机构信息

Department of Surgical Oncology, Rene Huguenin, Saint-Cloud, France

Department of Gynecology and Obstetrics, Lariboisiere Hospital, Paris, France.

出版信息

Anticancer Res. 2020 Feb;40(2):1095-1100. doi: 10.21873/anticanres.14048.

DOI:10.21873/anticanres.14048
PMID:32014959
Abstract

BACKGROUND/AIM: Fibroepithelial lesions (FEL) of the breast include fibroadenomas and phyllodes tumors (PT). Their histologic characteristics on core needle biopsy can overlap, while their clinical management is different. The aim of this study was to develop and to validate a pre-operative score for the diagnosis of PT with surgical decision rules.

PATIENTS AND METHODS

We developed a pre-operative score for the diagnosis of PT by performing logistic regression on 217 FEL of the Rene Huguenin Hospital. This score and the surgical decision rules were validated on 87 FEL of the Lariboisiere Hospital.

RESULTS

Three variables were independently and significantly associated with PT: age ≥40 years, mammography's tumor size ≥3 cm and PT diagnosed by CNB. The pre-operative score was based on these three criteria with values ranging from 0 to 10. Surgical decision rules were created: the low-risk group of PT (score≤2) had a sensitivity of 92.6% and a LR- of 0.2, the high-risk group (score>7) had a specificity of 93.5% and a LR+ of 4.4. In the validation sample, surgical decision rules were applied.

CONCLUSION

These surgical decision rules may prove useful in deciding which FEL needs surgical resection.

摘要

背景/目的:乳腺纤维上皮性病变(FEL)包括纤维腺瘤和叶状肿瘤(PT)。它们在核心针活检中的组织学特征可能重叠,而其临床管理则不同。本研究的目的是开发和验证术前评分,以用于具有手术决策规则的 PT 诊断。

患者和方法

我们通过对 Rene Huguenin 医院的 217 例 FEL 进行逻辑回归,制定了用于诊断 PT 的术前评分。该评分和手术决策规则在 Lariboisiere 医院的 87 例 FEL 中得到验证。

结果

三个变量与 PT 独立且显著相关:年龄≥40 岁、乳房 X 线摄影的肿瘤大小≥3cm 和 CNB 诊断为 PT。术前评分基于这三个标准,分值范围为 0 至 10。创建了手术决策规则:PT 的低危组(评分≤2)的敏感度为 92.6%,LR-为 0.2;高危组(评分>7)的特异度为 93.5%,LR+为 4.4。在验证样本中,应用了手术决策规则。

结论

这些手术决策规则可能有助于决定哪些 FEL 需要手术切除。

相似文献

1
A Pre-operative Score to Discriminate Fibroepithelial Lesions of the Breast: Phyllode Tumor or Fibroadenoma?术前评分鉴别乳腺纤维上皮性病变:叶状肿瘤还是纤维腺瘤?
Anticancer Res. 2020 Feb;40(2):1095-1100. doi: 10.21873/anticanres.14048.
2
Retrospective analysis of core-needle and vacuum-assisted breast biopsies of B3 fibroepithelial lesions and correlation with results in subsequent surgical specimens.回顾性分析 B3 型纤维上皮性病变的空心针和真空辅助活检与后续手术标本结果的相关性。
J Cancer Res Clin Oncol. 2024 Sep 28;150(9):436. doi: 10.1007/s00432-024-05934-9.
3
Core needle biopsy diagnosis of fibroepithelial lesions of the breast: a diagnostic challenge.乳腺纤维上皮性病变的粗针活检诊断:一项诊断挑战。
Pathology. 2020 Oct;52(6):627-634. doi: 10.1016/j.pathol.2020.06.005. Epub 2020 Aug 6.
4
Fibroepithelial breast lesions diagnosed by core needle biopsy demonstrate a moderate rate of upstaging to phyllodes tumors.经粗针活检诊断的乳腺纤维上皮性病变显示出向叶状肿瘤升级的中等发生率。
Am J Surg. 2017 Aug;214(2):318-322. doi: 10.1016/j.amjsurg.2016.12.017. Epub 2016 Dec 27.
5
Accuracy and clinical implications of pre-operative breast core needle biopsy diagnoses of fibroepithelial neoplasms and sarcomatoid carcinomas.术前乳腺核心针活检诊断纤维上皮性肿瘤和肉瘤样癌的准确性及临床意义。
Breast Cancer Res Treat. 2019 Nov;178(1):51-56. doi: 10.1007/s10549-019-05350-5. Epub 2019 Jul 22.
6
Development of a Management Algorithm for the Diagnosis of Cellular Fibroepithelial Lesions From Core Needle Biopsies.用于诊断粗针活检中细胞性纤维上皮性病变的管理算法的开发
Int J Surg Pathol. 2018 Dec;26(8):684-692. doi: 10.1177/1066896918775525. Epub 2018 May 18.
7
[Fibroepithelial tumours of the breast: not always a simple fibroadenoma].[乳腺纤维上皮性肿瘤:并非总是单纯的纤维腺瘤]
Ned Tijdschr Geneeskd. 2017;161:D886.
8
Diagnosis, characteristics, and treatment of breast carcinomas within benign fibroepithelial tumors.乳腺良性质纤维上皮肿瘤内的癌的诊断、特征和治疗。
Breast Cancer. 2018 Jul;25(4):470-478. doi: 10.1007/s12282-018-0847-7. Epub 2018 Feb 19.
9
Excision of breast fibroepithelial lesions: when is it still necessary?-A 10-year review of a regional centre.乳房纤维上皮性病变切除术:何时仍有必要?——区域性中心的 10 年回顾。
Breast Cancer Res Treat. 2022 Jul;194(2):307-314. doi: 10.1007/s10549-022-06631-2. Epub 2022 May 31.
10
Clinical and radiologic data and core needle biopsy findings should dictate management of cellular fibroepithelial tumors of the breast.临床和影像学数据以及核心针活检结果应决定乳腺细胞纤维上皮肿瘤的治疗方法。
Breast J. 2010 Nov-Dec;16(6):573-80. doi: 10.1111/j.1524-4741.2010.01013.x.

引用本文的文献

1
A convenient model based on mammography and magnetic resonance imaging for preoperative differentiation of breast phyllodes tumors and fibroadenomas.一种基于乳房X线摄影和磁共振成像的便捷模型,用于术前鉴别乳腺叶状肿瘤和纤维腺瘤。
Gland Surg. 2025 Jul 31;14(7):1306-1317. doi: 10.21037/gs-2025-145. Epub 2025 Jul 28.
2
Differentiation Between Phyllodes Tumor and Fibroadenoma of the Breast: A Radiomics Prediction Model Based on Full-Field Digital Mammography & Digital Tomosynthesis.乳腺叶状肿瘤与纤维腺瘤的鉴别:基于全数字化乳腺摄影与数字断层合成的放射组学预测模型。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241289474. doi: 10.1177/15330338241289474.
3
Differentiation between Phyllodes Tumors and Fibroadenomas through Breast Ultrasound: Deep-Learning Model Outperforms Ultrasound Physicians.
通过乳腺超声对叶状肿瘤和纤维腺瘤进行鉴别:深度学习模型优于超声医师。
Sensors (Basel). 2023 May 26;23(11):5099. doi: 10.3390/s23115099.
4
Predicting the pathological grade of breast phyllodes tumors: a nomogram based on clinical and magnetic resonance imaging features.预测乳腺叶状肿瘤的病理分级:基于临床和磁共振成像特征的列线图。
Br J Radiol. 2021 Aug 1;94(1124):20210342. doi: 10.1259/bjr.20210342. Epub 2021 Jul 8.
5
Quantitative proteome profiling stratifies fibroepithelial lesions of the breast.定量蛋白质组分析可对乳腺纤维上皮性病变进行分层。
Oncotarget. 2021 Mar 2;12(5):507-518. doi: 10.18632/oncotarget.27889.